Background IgA nephropathy is thought to be associated with mucosal immune system dysfunction, which manifests as renal IgA deposition that leads to impairment and end-stage renal disease in 20-40% of patients within 10-20 years. In this trial (NEFIGAN) we aimed to assess safety and efficacy of a novel targeted-release formulation of budesonide (TRF-budesonide), designed to deliver the drug to the distal ileum in patients with IgA nephropathy. Methods We did a randomised, double-blind, placebo-controlled phase 2b trial, comprised of 6-month run-in, 9-month treatment, and 3-month follow-up phases at 62 nephrology clinics across ten European countries. We recruited patients aged at least 18 years with biopsy-confirmed primary IgA nephropathy ...
Background. Currently, several therapeutic protocols exist for IgA nephropathy (IgAN); results in sl...
Background The role of change in proteinuria as a surrogate end point for randomized trials in immun...
Background. Currently, several therapeutic protocols exist for IgA nephropathy (IgAN); results in sl...
Background IgA nephropathy is thought to be associated with mucosal immune system dysfunction, which...
Background: IgA nephropathy is thought to be associated with mucosal immune system dysfunction, whic...
BACKGROUND: IgA nephropathy is thought to be associated with mucosal immune system dysfunction, whic...
The therapeutic potential of a novel, targeted-release formulation of oral budesonide (Nefecon) for ...
The therapeutic potential of a novel, targeted-release formulation of oral budesonide (Nefecon) for ...
IntroductionImmunoglobulin A nephropathy (IgAN) is characterized by mesangial deposition of immune c...
Budesonide; Transplant; NephropathyBudesonida; Trasplante; NefropatíaBudesonida; Trasplantament; Nef...
Importance Guidelines recommend corticosteroids in patients with IgA nephropathy and persistent pro...
BackgroundIgA nephropathy (IgAN) is the most common glomerulonephritis world-wide and a cause of end...
Background/Aims: The present network meta-analysis of randomized controlled trials (RCTs) was to exp...
Current guidelines suggest treatment with corticosteroids (CS) in IgA nephropathy (IgAN) when protei...
Current guidelines suggest treatment with corticosteroids (CS) in IgA nephropathy (IgAN) when protei...
Background. Currently, several therapeutic protocols exist for IgA nephropathy (IgAN); results in sl...
Background The role of change in proteinuria as a surrogate end point for randomized trials in immun...
Background. Currently, several therapeutic protocols exist for IgA nephropathy (IgAN); results in sl...
Background IgA nephropathy is thought to be associated with mucosal immune system dysfunction, which...
Background: IgA nephropathy is thought to be associated with mucosal immune system dysfunction, whic...
BACKGROUND: IgA nephropathy is thought to be associated with mucosal immune system dysfunction, whic...
The therapeutic potential of a novel, targeted-release formulation of oral budesonide (Nefecon) for ...
The therapeutic potential of a novel, targeted-release formulation of oral budesonide (Nefecon) for ...
IntroductionImmunoglobulin A nephropathy (IgAN) is characterized by mesangial deposition of immune c...
Budesonide; Transplant; NephropathyBudesonida; Trasplante; NefropatíaBudesonida; Trasplantament; Nef...
Importance Guidelines recommend corticosteroids in patients with IgA nephropathy and persistent pro...
BackgroundIgA nephropathy (IgAN) is the most common glomerulonephritis world-wide and a cause of end...
Background/Aims: The present network meta-analysis of randomized controlled trials (RCTs) was to exp...
Current guidelines suggest treatment with corticosteroids (CS) in IgA nephropathy (IgAN) when protei...
Current guidelines suggest treatment with corticosteroids (CS) in IgA nephropathy (IgAN) when protei...
Background. Currently, several therapeutic protocols exist for IgA nephropathy (IgAN); results in sl...
Background The role of change in proteinuria as a surrogate end point for randomized trials in immun...
Background. Currently, several therapeutic protocols exist for IgA nephropathy (IgAN); results in sl...